ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

TBRA Tobira Therapeutics, Inc.

42.09
0.00 (0.00%)
Pre Market
Last Updated: 20:00:00
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price 41.92
Ask Price 42.26
News -
Company Name Stock Ticker Symbol Market Type
Tobira Therapeutics, Inc. TBRA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 42.09 20:00:00
Open Price Low Price High Price Close Price Prev Close
42.09
Trades Volume Avg Volume
0 0 -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 42.09 USD

Tobira Therapeutics, Inc. Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 792.19M - - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Tobira Therapeutics, Inc. News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No TBRA Message Board. Create One! See More Posts on TBRA Message Board See More Message Board Posts

Historical TBRA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.000.000.000.0000.000.00%
3 Years0.000.000.000.0000.000.00%
5 Years0.000.000.000.0000.000.00%

Tobira Therapeutics, Inc. Description

Regado Biosciences Inc was incorporated in Delaware under the name Quartet Biosciences, Inc. in December 2001 and changed its name to Regado Biosciences, Inc. in March 2003. It is a biopharmaceutical company. The Company is engaged in the discovery and development of antithrombotic drug systems for acute and sub-acute cardiovascular indications. The Company's product candidates consists of a two-component system: an aptamer and its specific active control agent. The aptamer is administered first and achieves its therapeutic effect within minutes. When the therapeutic effect of the aptamer is no longer needed, the control agent is administered to rapidly and precisely reduce or eliminate it. The level of reduction is determined by the amount of control agent given compared to the aptamer dose. The Company's product candidate, REG1, consists of pegnivacogin, a highly potent and selective anticoagulant, and anivamersen, its specific active control agent.

Your Recent History

Delayed Upgrade Clock